Journal: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica

Article Title: IGSF3 tissue expression in squamous cell carcinoma of the oropharynx: a novel tool for prognosis assessment in HPV-related and HPV-unrelated disease.

doi: 10.1111/apm.13417

Figure Lengend Snippet: Fig. 2. (A) Negative, (B) Weak, (C) Moderate, and (D) Strong IGSF3 immunostaining in OPSCC TMA slides. Magnifica- tion x200, scale bar length 150 lm.

Article Snippet: As a primary antibody, we used the polyclonal Anti-IGSF3 antibody produced in rabbit (Prestige Antibodies by Atlas Antibodies, Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany).

Techniques: Immunostaining

Journal: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica

Article Title: IGSF3 tissue expression in squamous cell carcinoma of the oropharynx: a novel tool for prognosis assessment in HPV-related and HPV-unrelated disease.

doi: 10.1111/apm.13417

Figure Lengend Snippet: Fig. 3. Overall survival (OS) according to IGSF3 immu- nopositivity in tumor cells (TCs) in cohort I (C1).

Article Snippet: As a primary antibody, we used the polyclonal Anti-IGSF3 antibody produced in rabbit (Prestige Antibodies by Atlas Antibodies, Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany).

Techniques:

Journal: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica

Article Title: IGSF3 tissue expression in squamous cell carcinoma of the oropharynx: a novel tool for prognosis assessment in HPV-related and HPV-unrelated disease.

doi: 10.1111/apm.13417

Figure Lengend Snippet: Fig. 4. OS according to IGSF3 immunopositivity in tumor-infiltrating lymphocytes (TILs) in C1.

Article Snippet: As a primary antibody, we used the polyclonal Anti-IGSF3 antibody produced in rabbit (Prestige Antibodies by Atlas Antibodies, Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany).

Techniques:

Journal: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica

Article Title: IGSF3 tissue expression in squamous cell carcinoma of the oropharynx: a novel tool for prognosis assessment in HPV-related and HPV-unrelated disease.

doi: 10.1111/apm.13417

Figure Lengend Snippet: Fig. 5. OS according to IGSF3 immunopositivity in TCs in cohort II (C2).

Article Snippet: As a primary antibody, we used the polyclonal Anti-IGSF3 antibody produced in rabbit (Prestige Antibodies by Atlas Antibodies, Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany).

Techniques:

Journal: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica

Article Title: IGSF3 tissue expression in squamous cell carcinoma of the oropharynx: a novel tool for prognosis assessment in HPV-related and HPV-unrelated disease.

doi: 10.1111/apm.13417

Figure Lengend Snippet: Fig. 6. OS according to IGSF3 immunopositivity in TILs in C2.

Article Snippet: As a primary antibody, we used the polyclonal Anti-IGSF3 antibody produced in rabbit (Prestige Antibodies by Atlas Antibodies, Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany).

Techniques:

Journal: Annals of translational medicine

Article Title: The immunoglobulin superfamily member 3 (IGSF3) promotes hepatocellular carcinoma progression through activation of the NF-κB pathway.

doi: 10.21037/atm.2020.02.14

Figure Lengend Snippet: Figure 1 IGSF3 expression profiles in HCC and paired non-tumorous samples. (A) A representative western blotting image of IGSF3 in

Article Snippet: Table S4 Primary antibodies with indicated concentration for WB, IHC, IF Antibody Dilution Company Cat No. WB IHC IF IGSF3 1:400 1:400 1:50 Bioss Bs-9196R PCNA 1:250 BOSTR BM0104 cyclin A 1:250 BOSTER A00700 cyclin E 1:400 BOSTER A00543-1 CDK1 1:400 BOSTER BM0027 CDK2 1:400 BOSTER PB0562 p-IKBα 1:400 Wanleibio WL03120 IKBα 1:400 Wanleibio WL02495 IKBα 1:200 Beyotime AF1282 p-NF-κB 1:400 Wanleibio WL02169 NF-κB 1:400 Wanleibio WL01273b NF-κB 1:200 Beyotime AF1234 GAPDH 1:800 BOSTER BM3876 Ki-67 1:200 BOSTER PB0065 Lamin B 1:1,000 Bioss bs-1840R β-action 1:800 Bioss bsm-33036M Table S5 Relationship between IGSF3 expression and clinicopathologic features (n=49) Features Relative IGSF3 expression P value Low (n=23) High (n=26) Age 0.2092 ≤50 4 9 >50 19 17 Sex 0.1944 Male 22 21 Female 1 5 AFP (μg/L) 0.5276 ≤400 15 20 >400 8 6 HBV 0.7471 Positive 7 6 Negative 16 20 Tumor diameter (cm) 0.0001 ≤5 19 7 >5 4 19 TNM stage 0.0002 I–II 18 6 III–IV 5 20 Vascular invasion 0.1250 Yes 17 24 No 6 2 Lymph node metastasis 0.0045 Yes 0 8 No 23 18 Significance figures are P values for Fisher’s exact test.

Techniques: Expressing, Western Blot

Journal: Annals of translational medicine

Article Title: The immunoglobulin superfamily member 3 (IGSF3) promotes hepatocellular carcinoma progression through activation of the NF-κB pathway.

doi: 10.21037/atm.2020.02.14

Figure Lengend Snippet: Figure 2 IGSF3 promotes HCC cell proliferation in vitro. (A) Western blot analysis of IGSF3 in L02 and HCC cells (left panel);

Article Snippet: Table S4 Primary antibodies with indicated concentration for WB, IHC, IF Antibody Dilution Company Cat No. WB IHC IF IGSF3 1:400 1:400 1:50 Bioss Bs-9196R PCNA 1:250 BOSTR BM0104 cyclin A 1:250 BOSTER A00700 cyclin E 1:400 BOSTER A00543-1 CDK1 1:400 BOSTER BM0027 CDK2 1:400 BOSTER PB0562 p-IKBα 1:400 Wanleibio WL03120 IKBα 1:400 Wanleibio WL02495 IKBα 1:200 Beyotime AF1282 p-NF-κB 1:400 Wanleibio WL02169 NF-κB 1:400 Wanleibio WL01273b NF-κB 1:200 Beyotime AF1234 GAPDH 1:800 BOSTER BM3876 Ki-67 1:200 BOSTER PB0065 Lamin B 1:1,000 Bioss bs-1840R β-action 1:800 Bioss bsm-33036M Table S5 Relationship between IGSF3 expression and clinicopathologic features (n=49) Features Relative IGSF3 expression P value Low (n=23) High (n=26) Age 0.2092 ≤50 4 9 >50 19 17 Sex 0.1944 Male 22 21 Female 1 5 AFP (μg/L) 0.5276 ≤400 15 20 >400 8 6 HBV 0.7471 Positive 7 6 Negative 16 20 Tumor diameter (cm) 0.0001 ≤5 19 7 >5 4 19 TNM stage 0.0002 I–II 18 6 III–IV 5 20 Vascular invasion 0.1250 Yes 17 24 No 6 2 Lymph node metastasis 0.0045 Yes 0 8 No 23 18 Significance figures are P values for Fisher’s exact test.

Techniques: In Vitro, Western Blot

Journal: Annals of translational medicine

Article Title: The immunoglobulin superfamily member 3 (IGSF3) promotes hepatocellular carcinoma progression through activation of the NF-κB pathway.

doi: 10.21037/atm.2020.02.14

Figure Lengend Snippet: Figure 3 IGSF3 affects HCC cell proliferation in vitro. (A,B) Western blot analyses of cyclin A, cyclin E, CDK1, and CDK2 levels in

Article Snippet: Table S4 Primary antibodies with indicated concentration for WB, IHC, IF Antibody Dilution Company Cat No. WB IHC IF IGSF3 1:400 1:400 1:50 Bioss Bs-9196R PCNA 1:250 BOSTR BM0104 cyclin A 1:250 BOSTER A00700 cyclin E 1:400 BOSTER A00543-1 CDK1 1:400 BOSTER BM0027 CDK2 1:400 BOSTER PB0562 p-IKBα 1:400 Wanleibio WL03120 IKBα 1:400 Wanleibio WL02495 IKBα 1:200 Beyotime AF1282 p-NF-κB 1:400 Wanleibio WL02169 NF-κB 1:400 Wanleibio WL01273b NF-κB 1:200 Beyotime AF1234 GAPDH 1:800 BOSTER BM3876 Ki-67 1:200 BOSTER PB0065 Lamin B 1:1,000 Bioss bs-1840R β-action 1:800 Bioss bsm-33036M Table S5 Relationship between IGSF3 expression and clinicopathologic features (n=49) Features Relative IGSF3 expression P value Low (n=23) High (n=26) Age 0.2092 ≤50 4 9 >50 19 17 Sex 0.1944 Male 22 21 Female 1 5 AFP (μg/L) 0.5276 ≤400 15 20 >400 8 6 HBV 0.7471 Positive 7 6 Negative 16 20 Tumor diameter (cm) 0.0001 ≤5 19 7 >5 4 19 TNM stage 0.0002 I–II 18 6 III–IV 5 20 Vascular invasion 0.1250 Yes 17 24 No 6 2 Lymph node metastasis 0.0045 Yes 0 8 No 23 18 Significance figures are P values for Fisher’s exact test.

Techniques: In Vitro, Western Blot

Journal: Annals of translational medicine

Article Title: The immunoglobulin superfamily member 3 (IGSF3) promotes hepatocellular carcinoma progression through activation of the NF-κB pathway.

doi: 10.21037/atm.2020.02.14

Figure Lengend Snippet: Figure 4 IGSF3 enhances HCC cell migration and invasion in vitro. (A,B) Cell migration capability of HCLLM3 and hepG2 cells

Article Snippet: Table S4 Primary antibodies with indicated concentration for WB, IHC, IF Antibody Dilution Company Cat No. WB IHC IF IGSF3 1:400 1:400 1:50 Bioss Bs-9196R PCNA 1:250 BOSTR BM0104 cyclin A 1:250 BOSTER A00700 cyclin E 1:400 BOSTER A00543-1 CDK1 1:400 BOSTER BM0027 CDK2 1:400 BOSTER PB0562 p-IKBα 1:400 Wanleibio WL03120 IKBα 1:400 Wanleibio WL02495 IKBα 1:200 Beyotime AF1282 p-NF-κB 1:400 Wanleibio WL02169 NF-κB 1:400 Wanleibio WL01273b NF-κB 1:200 Beyotime AF1234 GAPDH 1:800 BOSTER BM3876 Ki-67 1:200 BOSTER PB0065 Lamin B 1:1,000 Bioss bs-1840R β-action 1:800 Bioss bsm-33036M Table S5 Relationship between IGSF3 expression and clinicopathologic features (n=49) Features Relative IGSF3 expression P value Low (n=23) High (n=26) Age 0.2092 ≤50 4 9 >50 19 17 Sex 0.1944 Male 22 21 Female 1 5 AFP (μg/L) 0.5276 ≤400 15 20 >400 8 6 HBV 0.7471 Positive 7 6 Negative 16 20 Tumor diameter (cm) 0.0001 ≤5 19 7 >5 4 19 TNM stage 0.0002 I–II 18 6 III–IV 5 20 Vascular invasion 0.1250 Yes 17 24 No 6 2 Lymph node metastasis 0.0045 Yes 0 8 No 23 18 Significance figures are P values for Fisher’s exact test.

Techniques: Migration, In Vitro

Journal: Annals of translational medicine

Article Title: The immunoglobulin superfamily member 3 (IGSF3) promotes hepatocellular carcinoma progression through activation of the NF-κB pathway.

doi: 10.21037/atm.2020.02.14

Figure Lengend Snippet: Figure 5 IGSF3 actives the NF-B signaling pathways. (A,B) Characteristic IF images of NF-κB and IKBα in cell transfected with shCON,

Article Snippet: Table S4 Primary antibodies with indicated concentration for WB, IHC, IF Antibody Dilution Company Cat No. WB IHC IF IGSF3 1:400 1:400 1:50 Bioss Bs-9196R PCNA 1:250 BOSTR BM0104 cyclin A 1:250 BOSTER A00700 cyclin E 1:400 BOSTER A00543-1 CDK1 1:400 BOSTER BM0027 CDK2 1:400 BOSTER PB0562 p-IKBα 1:400 Wanleibio WL03120 IKBα 1:400 Wanleibio WL02495 IKBα 1:200 Beyotime AF1282 p-NF-κB 1:400 Wanleibio WL02169 NF-κB 1:400 Wanleibio WL01273b NF-κB 1:200 Beyotime AF1234 GAPDH 1:800 BOSTER BM3876 Ki-67 1:200 BOSTER PB0065 Lamin B 1:1,000 Bioss bs-1840R β-action 1:800 Bioss bsm-33036M Table S5 Relationship between IGSF3 expression and clinicopathologic features (n=49) Features Relative IGSF3 expression P value Low (n=23) High (n=26) Age 0.2092 ≤50 4 9 >50 19 17 Sex 0.1944 Male 22 21 Female 1 5 AFP (μg/L) 0.5276 ≤400 15 20 >400 8 6 HBV 0.7471 Positive 7 6 Negative 16 20 Tumor diameter (cm) 0.0001 ≤5 19 7 >5 4 19 TNM stage 0.0002 I–II 18 6 III–IV 5 20 Vascular invasion 0.1250 Yes 17 24 No 6 2 Lymph node metastasis 0.0045 Yes 0 8 No 23 18 Significance figures are P values for Fisher’s exact test.

Techniques: Protein-Protein interactions, Transfection

Journal: Annals of translational medicine

Article Title: The immunoglobulin superfamily member 3 (IGSF3) promotes hepatocellular carcinoma progression through activation of the NF-κB pathway.

doi: 10.21037/atm.2020.02.14

Figure Lengend Snippet: Figure 6 IGSF3 promotes HCC cell proliferation in vivo. (A) Characteristic images of the BALB/c nude mice bearing HCC tumor; (B) the

Article Snippet: Table S4 Primary antibodies with indicated concentration for WB, IHC, IF Antibody Dilution Company Cat No. WB IHC IF IGSF3 1:400 1:400 1:50 Bioss Bs-9196R PCNA 1:250 BOSTR BM0104 cyclin A 1:250 BOSTER A00700 cyclin E 1:400 BOSTER A00543-1 CDK1 1:400 BOSTER BM0027 CDK2 1:400 BOSTER PB0562 p-IKBα 1:400 Wanleibio WL03120 IKBα 1:400 Wanleibio WL02495 IKBα 1:200 Beyotime AF1282 p-NF-κB 1:400 Wanleibio WL02169 NF-κB 1:400 Wanleibio WL01273b NF-κB 1:200 Beyotime AF1234 GAPDH 1:800 BOSTER BM3876 Ki-67 1:200 BOSTER PB0065 Lamin B 1:1,000 Bioss bs-1840R β-action 1:800 Bioss bsm-33036M Table S5 Relationship between IGSF3 expression and clinicopathologic features (n=49) Features Relative IGSF3 expression P value Low (n=23) High (n=26) Age 0.2092 ≤50 4 9 >50 19 17 Sex 0.1944 Male 22 21 Female 1 5 AFP (μg/L) 0.5276 ≤400 15 20 >400 8 6 HBV 0.7471 Positive 7 6 Negative 16 20 Tumor diameter (cm) 0.0001 ≤5 19 7 >5 4 19 TNM stage 0.0002 I–II 18 6 III–IV 5 20 Vascular invasion 0.1250 Yes 17 24 No 6 2 Lymph node metastasis 0.0045 Yes 0 8 No 23 18 Significance figures are P values for Fisher’s exact test.

Techniques: In Vivo

Journal: Annals of translational medicine

Article Title: The immunoglobulin superfamily member 3 (IGSF3) promotes hepatocellular carcinoma progression through activation of the NF-κB pathway.

doi: 10.21037/atm.2020.02.14

Figure Lengend Snippet: Figure 7 IGSF3 promotes HCC cell cycle and NF-B signaling pathways in vivo. (A) Western blot analyses of cyclin A, cyclin E, CDK1,

Article Snippet: Table S4 Primary antibodies with indicated concentration for WB, IHC, IF Antibody Dilution Company Cat No. WB IHC IF IGSF3 1:400 1:400 1:50 Bioss Bs-9196R PCNA 1:250 BOSTR BM0104 cyclin A 1:250 BOSTER A00700 cyclin E 1:400 BOSTER A00543-1 CDK1 1:400 BOSTER BM0027 CDK2 1:400 BOSTER PB0562 p-IKBα 1:400 Wanleibio WL03120 IKBα 1:400 Wanleibio WL02495 IKBα 1:200 Beyotime AF1282 p-NF-κB 1:400 Wanleibio WL02169 NF-κB 1:400 Wanleibio WL01273b NF-κB 1:200 Beyotime AF1234 GAPDH 1:800 BOSTER BM3876 Ki-67 1:200 BOSTER PB0065 Lamin B 1:1,000 Bioss bs-1840R β-action 1:800 Bioss bsm-33036M Table S5 Relationship between IGSF3 expression and clinicopathologic features (n=49) Features Relative IGSF3 expression P value Low (n=23) High (n=26) Age 0.2092 ≤50 4 9 >50 19 17 Sex 0.1944 Male 22 21 Female 1 5 AFP (μg/L) 0.5276 ≤400 15 20 >400 8 6 HBV 0.7471 Positive 7 6 Negative 16 20 Tumor diameter (cm) 0.0001 ≤5 19 7 >5 4 19 TNM stage 0.0002 I–II 18 6 III–IV 5 20 Vascular invasion 0.1250 Yes 17 24 No 6 2 Lymph node metastasis 0.0045 Yes 0 8 No 23 18 Significance figures are P values for Fisher’s exact test.

Techniques: Protein-Protein interactions, In Vivo, Western Blot